{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T12:47:07Z","timestamp":1771505227336,"version":"3.50.1"},"reference-count":53,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>MicroRNAs (miRNAs) are master regulators of drug resistance and have been previously proposed as potential biomarkers for the prediction of therapeutic response in colorectal cancer (CRC). Sorafenib, a multi-kinase inhibitor which has been approved for the treatment of liver, renal and thyroid cancer, is currently being studied as a monotherapy in selected molecular subtypes or in combination with other drugs in metastatic CRC. In this study, we explored sorafenib-induced cellular effects in Kirsten rat sarcoma viral oncogene homolog olog (KRAS) wild-type and KRAS-mutated CRC cell lines (Caco-2 and HRT-18), and finally profiled expression changes of specific miRNAs within the miRNome (&gt;1000 human miRNAs) after exposure to sorafenib. Overall, sorafenib induced a time- and dose-dependent growth-inhibitory effect through S-phase cell cycle arrest in KRAS wild-type and KRAS-mutated CRC cells. In HRT-18 cells, two human miRNAs (hsa-miR-597 and hsa-miR-720) and two small RNAs (SNORD 13 and hsa-miR-3182) were identified as specifically sorafenib-induced. In Caco-2 cells, nine human miRNAs (hsa-miR-3142, hsa-miR-20a, hsa-miR-4301, hsa-miR-1290, hsa-miR-4286, hsa-miR-3182, hsa-miR-3142, hsa-miR-1246 and hsa-miR-720) were identified to be differentially regulated post sorafenib treatment. In conclusion, we confirmed sorafenib as a potential anti-neoplastic treatment strategy for CRC cells by demonstrating a growth-inhibitory and cell cycle\u2013arresting effect of this drug. Changes in the miRNome indicate that some specific miRNAs might be relevant as indicators for sorafenib response, drug resistance and potential targets for combinatorial miRNA-based drug strategies.<\/jats:p>","DOI":"10.3390\/ijms17122011","type":"journal-article","created":{"date-parts":[[2016,12,2]],"date-time":"2016-12-02T10:36:37Z","timestamp":1480674997000},"page":"2011","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Comprehensive Analysis of miRNome Alterations in Response to Sorafenib Treatment in Colorectal Cancer Cells"],"prefix":"10.3390","volume":"17","author":[{"given":"Anna-Maria","family":"Pehserl","sequence":"first","affiliation":[{"name":"Division of Oncology, Department of Internal Medicine, Medical University of Graz, 8010 Graz, Austria"},{"name":"Research Unit of Non-Coding RNA and Genome Editing in Cancer, Medical University of Graz, 8010 Graz, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Ress","sequence":"additional","affiliation":[{"name":"Division of Oncology, Department of Internal Medicine, Medical University of Graz, 8010 Graz, Austria"},{"name":"Research Unit of Non-Coding RNA and Genome Editing in Cancer, Medical University of Graz, 8010 Graz, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefanie","family":"Stanzer","sequence":"additional","affiliation":[{"name":"Division of Oncology, Department of Internal Medicine, Medical University of Graz, 8010 Graz, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margit","family":"Resel","sequence":"additional","affiliation":[{"name":"Division of Oncology, Department of Internal Medicine, Medical University of Graz, 8010 Graz, Austria"},{"name":"Research Unit of Non-Coding RNA and Genome Editing in Cancer, Medical University of Graz, 8010 Graz, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Karbiener","sequence":"additional","affiliation":[{"name":"Department of Phoniatrics, ENT University Hospital, Medical University, 8010 Graz, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elke","family":"Stadelmeyer","sequence":"additional","affiliation":[{"name":"Institute of Pathology, Medical University of Graz, 8010 Graz, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Verena","family":"Stiegelbauer","sequence":"additional","affiliation":[{"name":"Division of Oncology, Department of Internal Medicine, Medical University of Graz, 8010 Graz, Austria"},{"name":"Research Unit of Non-Coding RNA and Genome Editing in Cancer, Medical University of Graz, 8010 Graz, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Armin","family":"Gerger","sequence":"additional","affiliation":[{"name":"Division of Oncology, Department of Internal Medicine, Medical University of Graz, 8010 Graz, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Mayr","sequence":"additional","affiliation":[{"name":"Laboratory for Tumour Biology and Experimental Therapies (TREAT), Institute of Physiology and Pathophysiology, Paracelsus Medical University, 5020 Salzburg, Austria"},{"name":"Department of Internal Medicine I, Salzburger Landeskliniken, Paracelsus Medical University, 5020 Salzburg, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4650-7387","authenticated-orcid":false,"given":"Marcel","family":"Scheideler","sequence":"additional","affiliation":[{"name":"Institute for Diabetes and Cancer (IDC), Helmholtz Zentrum M\u00fcnchen, German Research Center for Environmental Health, 85764 Neuherberg, Germany"},{"name":"Joint Heidelberg-IDC Translational Diabetes Program, Heidelberg University Hospital, 69120 Heidelberg, Germany"},{"name":"Molecular Metabolic Control, Medical Faculty, Technical University Munich, 85764 Munich, Germany"},{"name":"German Center for Diabetes Research (DZD), 85764 Neuherberg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georg","family":"Hutterer","sequence":"additional","affiliation":[{"name":"Department of Urology, Medical University of Graz, 8010 Graz, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Bauernhofer","sequence":"additional","affiliation":[{"name":"Division of Oncology, Department of Internal Medicine, Medical University of Graz, 8010 Graz, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tobias","family":"Kiesslich","sequence":"additional","affiliation":[{"name":"Laboratory for Tumour Biology and Experimental Therapies (TREAT), Institute of Physiology and Pathophysiology, Paracelsus Medical University, 5020 Salzburg, Austria"},{"name":"Department of Internal Medicine I, Salzburger Landeskliniken, Paracelsus Medical University, 5020 Salzburg, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8701-9462","authenticated-orcid":false,"given":"Martin","family":"Pichler","sequence":"additional","affiliation":[{"name":"Division of Oncology, Department of Internal Medicine, Medical University of Graz, 8010 Graz, Austria"},{"name":"Research Unit of Non-Coding RNA and Genome Editing in Cancer, Medical University of Graz, 8010 Graz, Austria"},{"name":"Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2016,12,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3322\/caac.21262","article-title":"Global cancer statistics","volume":"65","author":"Torre","year":"2015","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21332","article-title":"Cancer statistics","volume":"66","author":"Siegel","year":"2016","journal-title":"CA Cancer J. Clin."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/0168-9525(93)90209-Z","article-title":"The multistep nature of cancer","volume":"9","author":"Vogelstein","year":"1993","journal-title":"Trends Genet."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s12307-008-0007-2","article-title":"Role of cancer microenvironment in metastasis: Focus on colon cancer","volume":"1","author":"Gout","year":"2008","journal-title":"Cancer Microenviron."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.leukres.2005.10.017","article-title":"MicroRNAs and leukemias: How strong is the connection?","volume":"30","author":"Calin","year":"2006","journal-title":"Leuk. Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0092-8674(04)00045-5","article-title":"Micrornas: Genomics, biogenesis, mechanism, and function","volume":"116","author":"Bartel","year":"2004","journal-title":"Cell"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1146\/annurev-pathol-012513-104715","article-title":"MicroRNAs in cancer","volume":"9","author":"Garofalo","year":"2014","journal-title":"Annu. Rev. Pathol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"28063","DOI":"10.3390\/ijms161226080","article-title":"MicroRNAs: Clinical relevance in colorectal cancer","volume":"16","author":"Thomas","year":"2015","journal-title":"Int. J. Mol. Sci."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1586\/14737159.2014.946907","article-title":"An update on microRNAs as colorectal cancer biomarkers: Where are we and what's next?","volume":"14","author":"Okugawa","year":"2014","journal-title":"Expert Rev. Mol. Diagn."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1200\/JCO.2008.20.6771","article-title":"Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the mosaic trial","volume":"27","author":"Andre","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Papadimitriou, C.A., Papakostas, P., Karina, M., Malettou, L., Dimopoulos, M.A., Pentheroudakis, G., Samantas, E., Bamias, A., Miliaras, D., and Basdanis, G. (2011). A randomized phase III trial of adjuvant chemotherapy with irinotecan, leucovorin and fluorouracil versus leucovorin and fluorouracil for stage II and III colon cancer: A hellenic cooperative oncology group study. BMC Med., 9.","DOI":"10.1186\/1741-7015-9-10"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.2217\/pgs.15.83","article-title":"Genetic markers of recurrence in colorectal cancer","volume":"16","author":"Smolle","year":"2015","journal-title":"Pharmacogenomics"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/j.1872-034X.2012.01113.x","article-title":"Role of sorafenib in the treatment of advanced hepatocellular carcinoma: An update","volume":"43","author":"Gauthier","year":"2013","journal-title":"Hepatol. Res."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Brose, M.S., Nutting, C.M., Sherman, S.I., Shong, Y.K., Smit, J.W., Reike, G., Chung, J., Kalmus, J., Kappeler, C., and Schlumberger, M. (2011). Rationale and design of decision: A double-blind, randomized, placebo-controlled phase III trial evaluating the efficacy and safety of sorafenib in patients with locally advanced or metastatic radioactive iodine (RAI)-refractory, differentiated thyroid cancer. BMC Cancer, 11.","DOI":"10.1186\/1471-2407-11-349"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","article-title":"Efficacy and safety of sorafenib in patients in the asia-pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo-controlled trial","volume":"10","author":"Cheng","year":"2009","journal-title":"Lancet Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1200\/JCO.2008.19.5511","article-title":"Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial","volume":"27","author":"Escudier","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ejca.2006.08.032","article-title":"Results from an in vitro and a clinical\/pharmacological phase I study with the combination irinotecan and sorafenib","volume":"43","author":"Mross","year":"2007","journal-title":"Eur. J. Cancer"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"188","DOI":"10.3816\/CCC.2005.n.030","article-title":"Results of a phase I trial of sorafenib (bay 43\u20139006) in combination with oxaliplatin in patients with refractory solid tumors, including colorectal cancer","volume":"5","author":"Kupsch","year":"2005","journal-title":"Clin. Colorectal Cancer"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1158\/1078-0432.CCR-13-0107","article-title":"Sorafenib in combination with oxaliplatin, leucovorin, and fluorouracil (modified folfox6) as first-line treatment of metastatic colorectal cancer: The respect trial","volume":"19","author":"Tabernero","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1002\/path.4138","article-title":"Targeting flip and MCL-1 using a combination of aspirin and sorafenib sensitizes colon cancer cells to trail","volume":"229","author":"Pennarun","year":"2013","journal-title":"J. Pathol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1038\/bjc.2013.813","article-title":"Sorafenib and irinotecan (nexiri) as second- or later-line treatment for patients with metastatic colorectal cancer and KRAS-mutated tumours: A multicentre phase I\/II trial","volume":"110","author":"Samalin","year":"2014","journal-title":"Br. J. Cancer"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1158\/1078-0432.CCR-15-1681","article-title":"A phase I study of the safety, pharmacokinetics, and pharmacodynamics of combination therapy with refametinib plus sorafenib in patients with advanced cancer","volume":"22","author":"Adjei","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/bjc.2015.253","article-title":"MicroRNAs in cancer: From developmental genes in worms to their clinical application in patients","volume":"113","author":"Pichler","year":"2015","journal-title":"Br. J. Cancer"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1517\/14728222.2015.1071354","article-title":"Hepatocellular carcinoma treatment over sorafenib: Epigenetics, microRNAs and microenvironment. Is there a light at the end of the tunnel?","volume":"19","author":"Gnoni","year":"2015","journal-title":"Expert Opin. Ther. Targets"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1093\/carcin\/bgs203","article-title":"Sorafenib enhances the therapeutic efficacy of rapamycin in colorectal cancers harboring oncogenic KRAS and PIK3CA","volume":"33","author":"Gulhati","year":"2012","journal-title":"Carcinogenesis"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1038\/sj.bjc.6602584","article-title":"Phase I safety and pharmacokinetics of bay 43\u20139006 administered for 21 days on\/7 days off in patients with advanced, refractory solid tumours","volume":"92","author":"Awada","year":"2005","journal-title":"Br. J. Cancer"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1038\/bjc.2014.51","article-title":"miR-200a regulates epithelial to mesenchymal transition-related gene expression and determines prognosis in colorectal cancer patients","volume":"110","author":"Pichler","year":"2014","journal-title":"Br. J. Cancer"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Broecker-Preuss, M., M\u00fcller, S., Britten, M., Worm, K., Schmid, K.W., Mann, K., and Fuhrer, D. (2015). Sorafenib inhibits intracellular signaling pathways and induces cell cycle arrest and cell death in thyroid carcinoma cells irrespective of histological origin or BRAF mutational status. BMC Cancer, 15.","DOI":"10.1186\/s12885-015-1186-0"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"3519","DOI":"10.1158\/1535-7163.MCT-08-0138","article-title":"Sorafenib inhibits STAT3 signaling associated with growth arrest and apoptosis of medulloblastomas","volume":"7","author":"Yang","year":"2008","journal-title":"Mol. Cancer Ther."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.jphotobiol.2013.01.012","article-title":"Comprehensive analysis of alterations in the mirnome in response to photodynamic treatment","volume":"120","author":"Bach","year":"2013","journal-title":"J. Photochem. Photobiol. B"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1007\/s13277-014-2697-z","article-title":"Evaluation of miR-720 prognostic significance in patients with colorectal cancer","volume":"36","author":"Wang","year":"2015","journal-title":"Tumour Biol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.3892\/ijo.2015.3064","article-title":"Circulating miR-103 and miR-720 as novel serum biomarkers for patients with colorectal cancer","volume":"47","author":"Nonaka","year":"2015","journal-title":"Int. J. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"16226","DOI":"10.3390\/ijms140816226","article-title":"Involvement of miR-20a in promoting gastric cancer progression by targeting early growth response 2 (EGR2)","volume":"14","author":"Li","year":"2013","journal-title":"Int. J. Mol. Sci."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e152","DOI":"10.1038\/ctg.2016.11","article-title":"Expression profiles of mirna subsets distinguish human colorectal carcinoma and normal colonic mucosa","volume":"7","author":"Pellatt","year":"2016","journal-title":"Clin. Transl. Gastroenterol."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Xiong, Y., Zhang, L., and Kebebew, E. (2014). miR-20a is upregulated in anaplastic thyroid cancer and targets LIMK1. PLoS ONE, 23.","DOI":"10.1371\/journal.pone.0096103"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.4161\/cbt.29821","article-title":"miR-20a inhibits cutaneous squamous cell carcinoma metastasis and proliferation by directly targeting LIMK1","volume":"15","author":"Zhou","year":"2014","journal-title":"Cancer Biol. Ther."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Zhao, S., Yao, D., Chen, J., Ding, N., and Ren, F. (2015). miR-20a promotes cervical cancer proliferation and metastasis in vitro and in vivo. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0120905"},{"key":"ref_38","first-page":"1570","article-title":"miR-1290 is a potential prognostic biomarker in non-small cell lung cancer","volume":"7","author":"Mo","year":"2015","journal-title":"J. Thorac. Dis."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Janiszewska, J., Szaumkessel, M., Kostrzewska-Poczekaj, M., Bednarek, K., Paczkowska, J., Jackowska, J., Grenman, R., Szyfter, K., Wierzbicka, M., and Giefing, M. (2015). Global miRNA expression profiling identifies miR-1290 as novel potential oncomiR in laryngeal carcinoma. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0144924"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"189","DOI":"10.3892\/mco.2016.875","article-title":"Profiling analysis of circulating microRNA expression in cervical cancer","volume":"5","author":"Nagamitsu","year":"2016","journal-title":"Mol. Clin. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.3892\/etm.2012.531","article-title":"MicroRNA expression pattern and its alteration following celecoxib intervention in human colorectal cancer","volume":"3","author":"Chen","year":"2012","journal-title":"Exp. Ther. Med."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Pichler, M., Stiegelbauer, V., Vychytilova-Faltejskova, P., Ivan, C., Ling, H., Winter, E., Zhang, X., Goblirsch, M., Wulf-Goldenberg, A., and Ohtsuka, M. (2016). Genome-wide microRNA analysis identifies miR-188\u20133p as novel prognostic marker and molecular factor involved in colorectal carcinogenesis. Clin. Cancer Res., in press.","DOI":"10.1158\/1078-0432.CCR-16-0497"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.cancergen.2012.08.003","article-title":"MicroRNA profiling predicts survival in anti-EGFR treated chemorefractory metastatic colorectal cancer patients with wild-type KRAS and BRAF","volume":"205","author":"Mosakhani","year":"2012","journal-title":"Cancer Genet."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"9508","DOI":"10.1074\/jbc.M112.367763","article-title":"MicroRNA-31 activates the ras pathway and functions as an oncogenic microRNA in human colorectal cancer by repressing RAS p21 GTpase activating protein 1 (RASA1)","volume":"288","author":"Sun","year":"2013","journal-title":"J. Biol. Chem."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1245\/s10434-014-4264-7","article-title":"Association of microRNA-31\u20135p with clinical efficacy of anti-EGFR therapy in patients with metastatic colorectal cancer","volume":"22","author":"Igarashi","year":"2015","journal-title":"Ann. Surg. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"3338","DOI":"10.1158\/1078-0432.CCR-13-2750","article-title":"Hsa-miR-31\u20133p expression is linked to progression-free survival in patients with KRAS wild-type metastatic colorectal cancer treated with anti-EGFR therapy","volume":"20","author":"Manceau","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"38695","DOI":"10.18632\/oncotarget.5735","article-title":"MicroRNA expression profiling identifies miR-31\u20135p\/3p as associated with time to progression in wild-type RAS metastatic colorectal cancer treated with cetuximab","volume":"6","author":"Mlcochova","year":"2015","journal-title":"Oncotarget"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"4955","DOI":"10.21873\/anticanres.11063","article-title":"Efficacy and toxicity of panitumumab after progression on cetuximab and predictive value of miR-31\u20135p in metastatic wild-type KRAS colorectal cancer patients","volume":"36","author":"Kiss","year":"2016","journal-title":"Anticancer Res."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"11851","DOI":"10.1158\/0008-5472.CAN-06-1377","article-title":"Sorafenib blocks the raf\/mek\/erk pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model plc\/prf\/5","volume":"66","author":"Liu","year":"2006","journal-title":"Cancer Res."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"8492","DOI":"10.18632\/oncotarget.2329","article-title":"Spinophilin expression determines cellular growth, cancer stemness and 5-flourouracil resistance in colorectal cancer","volume":"5","author":"Ress","year":"2014","journal-title":"Oncotarget"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/978-1-4939-2547-6_15","article-title":"Microarray analysis of small non-coding RNAs","volume":"1296","author":"Karbiener","year":"2015","journal-title":"Methods Mol. Biol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1093\/bioinformatics\/bth174","article-title":"Arraynorm: Comprehensive normalization and analysis of microarray data","volume":"20","author":"Pieler","year":"2004","journal-title":"Bioinformatics"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1093\/bioinformatics\/18.1.207","article-title":"Genesis: Cluster analysis of microarray data","volume":"18","author":"Sturn","year":"2002","journal-title":"Bioinformatics"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/17\/12\/2011\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T19:27:48Z","timestamp":1760210868000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/17\/12\/2011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12,1]]},"references-count":53,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2016,12]]}},"alternative-id":["ijms17122011"],"URL":"https:\/\/doi.org\/10.3390\/ijms17122011","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12,1]]}}}